Table 2.
Radiotherapy characteristics (n = 593 patients).
| Pre-operative Radiotherapy | |
|---|---|
| Number of patients, n (%) | 477 (80.5) |
| Median rectal EQD2, Gy (Q1-Q3) | 49.2 (44–50) |
| Median duration, weeks (Q1-Q3) | 4.9 (4.3–5.1) |
| Median dose per fraction, Gy/fr (Q1-Q3) | 2 (1.8–2.1) |
| Median time to surgery, weeks (Q1-Q3) | 6.7 (6–7.5) |
| Fractionation | |
| Normofractionated schemes (1.8–2.4 Gy/fr), n (%) | 362 (61) |
| Hypofractionated schemes (≥2.5 Gy/fr), n (%) | 115 (19.5) |
| Post-operative Radiotherapy | |
| Number of patients, n (%) | 75 (12.6) |
| Median rectal EQD2, Gy (Q1-Q3) | 47.7 (43.9–50) |
| Median duration, weeks (Q1-Q3) | 4.6 (4.4–5.1) |
| Median dose per fraction, Gy/fr (Q1-Q3) | 2 (1.8–2.4) |
| Median time to surgery, weeks (Q1-Q3) | 10.3 (7.8–14.9) |
| Fractionation | |
| Normofractionated schemes (1.8–2.4 Gy/fr, n (%) | 56 (9.4) |
| Hypofractionated schemes (≥2.5 Gy/fr), n (%) | 19 (3.2) |
| Exclusive radiotherapy | |
| Number of patients, n (%) | 41 (6.9) |
| Median rectal EQD2, Gy (Q1-Q3) | 47.7 (43.9–50) |
| Median duration, weeks (Q1-Q3) | 4.4 (2.9–5.3) |
| Median dose per fraction, Gy/fr (Q1-Q3) | 2.5 (2–3) |
| Fractionation | |
| Normofractionated schemes (1.8–2.4 Gy/fr,) n (%) | 18 (3) |
| Hypofractionated schemes (≥2.5 Gy/fr), n (%) | 23 (3.9) |
Q1: first interquartile, Q3: third interquartile, EQD2: 2Gy-per-fraction equivalent dose, n: number of patients, Gy/fr: Gray per fraction.